Of mirtazapine and fluoxetine in treatment of senile depression control study.docVIP

 PAGE \* MERGEFORMAT 12 Of mirtazapine and fluoxetine in treatment of senile depression control study 【Abstract】 Objective To compare the mirtazapine and fluoxetine in the treatment of senile depression clinical efficacy and safety. Methods 120 elderly patients with depression were randomly divided into two groups of 60 cases of study group was treated with mirtazapine treatment, the control group was treated with fluoxetine treatment, observation 6 w. Pre-treatment and treatment in the first 1 w, 2 w, 4 w, 6 w end use of Hamilton Depression Rating Scale, side effects rating scale of clinical efficacy and adverse reactions. Results 6 w end of study group was 88.33% in the control group was 85%, the two groups showed no significant difference (Pgt; 0  05). Hamilton Depression Rating Scale score 1 w the two groups of treatment than those before treatment since the end of a very significant decrease (P lt;0.01); However, the study group of treatment 1 w, 2 w at the end than the control group decreased significantly (P lt; 0.01), the first 4 w at the end the difference was significant (P lt;0  05), No. 6 w at the end was no significant difference (Pgt; 0.05). Two sets of adverse reactions were mild. Conclusion Mirtazapine treatment of senile depression with fluoxetine in general quite effective, but the onset of mirtazapine faster, and can improve the anxiety symptoms, high security, compliance is good. Keywords: depression in the elderly; Mirtazapine; Fluoxetine Mirtazapine is a new kind of norepinephrine (NE) energy and specificity of 5  HT (5  HT) can be antidepressants, some studies [1 ~ 3] showed that mirtazapine can be a rapid increase in NE and 5  HT release, when the blocking a2 homologous receptors, an increase in NE release; when blocking a2 heterologous receptors, an increase in 5  HT release, he has a good anti-depressant and anxiolytic dual role. To explore the Mirtazapine treatment of senile depression the clinical efficacy